BeiGene to Present at the Deutsche Bank 43rd Annual Health Care Conference
| RegularNews read more...
May 01, 2018
BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.
| RegularNews read more...
Apr 16, 2018
BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting
| RegularNews read more...
Apr 16, 2018
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
| RegularNews read more...
Apr 10, 2018
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma
| RegularNews read more...
Apr 03, 2018
BeiGene Appoints J. Samuel Su to its Board of Directors
| RegularNews read more...
Mar 05, 2018
BeiGene to Present at Upcoming Investor Conferences
| RegularNews read more...
Feb 28, 2018
BeiGene Reports Fourth Quarter and Full Year 2017 Financial Results
| RegularNews read more...
Feb 27, 2018
BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China
| RegularNews read more...
Feb 09, 2018
BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers Symposium
| RegularNews read more...
Feb 07, 2018
BeiGene to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
| RegularNews read more...
Feb 05, 2018
BeiGene Announces Commercial Availability of VIDAZA® (Azacitidine for Injection) in China
| RegularNews read more...
Feb 05, 2018
BeiGene to Present Tislelizumab Data in Urothelial Carcinoma at the 2018 Genitourinary Cancers Symposium
| RegularNews read more...
Jan 31, 2018
BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma
| RegularNews read more...
Jan 22, 2018
BeiGene Announces Closing of $800 Million Public Offering
| RegularNews read more...
Jan 17, 2018
BeiGene Announces Pricing of $750 Million Public Offering
| RegularNews read more...
Jan 16, 2018
BeiGene Announces Proposed Public Offering
| RegularNews read more...
Jan 09, 2018
BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab
| RegularNews read more...
